Daraxonrasib is the first drug to substantially extend survival in pancreatic cancer trials. Median survival reached 13+ months compared to <7 months for chemo. It finally shuts down the "undruggable" KRAS protein, once called a greasy ball, using a novel molecular glue.
#MedSky
